We found that the TRPV4 inhibitor (HC067047) significantly relieved bone cancer pain, which causes overexpression of TET1 and TRPV4, and that inhibition of TET1 reduces TRPV4 expression (Figure 6 and Figure 7). This evidence concerns the gene TRPV4 and bone neoplasm.